Compare Crispr Therapeutics AG (CRSP) vs Opendoor Technologies Inc (OPEN) Price & Performance

CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.

The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.

Opendoor (OPEN) trades at $4.485, down 5.86% today, reflecting ongoing volatility amid a challenging housing market. The stock shows a bearish technical trend with support near $4 and resistance at $5. Fundamentally, the company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net margin of 35.25%. Recent news highlights CEO leadership and a shift toward AI, including the closure of India operations affecting 250 employees (Reuters, 2026-06-11).

The outlook remains cautious due to persistent losses and high debt, though the low P/S ratio of 0.94 offers some valuation appeal. Risks include execution of the new business model, interest rate sensitivity, and competitive pressure. Analyst sentiment is mixed with 65.39% hold ratings, indicating wait-and-see approach until sustained profitability emerges.